Year archive

Swedish Orphan Biovitrum — 2010 filings

All 78 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2010, sourced directly from the official regulator.

78 Filings

2010 Period

2010 filings (78)

Filing	Released	Lang
Swedish Orphan Biovitrum återlämnar rättigheterna för utveckling av Sym001 till Symphogen Regulatory Filings	2010-12-30	Swedish
Swedish Orphan Biovitrum returns development rights to Sym001 to Symphogen Regulatory Filings	2010-12-30	English
Styrelsen för Swedish Orphan Biovitrum AB (publ) utnyttjar återköpsbemyndigande för säkring av bolagets prestationsbaserade, långsiktiga aktieprogram Transaction in Own Shares	2010-12-23	Swedish
The board of directors of Swedish Orphan Biovitrum AB (publ) utilizes authorization to repurchase shares to secure the company's performance based, long-term share programs Transaction in Own Shares	2010-12-23	English
Swedish Orphan Biovitrum kommer att kunna utöka tillgängligheten av Willfact® till von Willebrand patienter då LFB BIOMEDICAMENTS har erhållit utvidgat europeiskt myndighetsgodkännande Regulatory Filings	2010-12-20	Swedish
Swedish Orphan Biovitrum to increase the availability of Willfact® to von Willebrand patients as LFB BIOMEDICAMENTS has received additional European regulatory approvals Regulatory Filings	2010-12-20	English
Biogen Idec and Swedish Orphan Biovitrum meddelar att första patienten har doserats i en global registreringstudie med långverkande rekombinant faktor VIII fusionsprotein. Regulatory Filings	2010-12-06	Swedish
Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Lasting Recombinant Factor VIII Fc Fusion Protein Regulatory Filings	2010-12-06	English
VD Martin Nicklasson lämnar Swedish Orphan Biovitrum Board/Management Information	2010-11-25	Swedish
CEO Martin Nicklasson leaves Swedish Orphan Biovitrum Board/Management Information	2010-11-25	English
Swedish Orphan Biovitrums co-promotionrättigheter för Mimpara® återgår till Amgen Regulatory Filings	2010-11-05	Swedish
Swedish Orphan Biovitrum's co-promotion rights for Mimpara® sold back to Amgen Regulatory Filings	2010-11-05	English
Swedish Orphan Biovitrum utser Anders Edvell till ny chef för marknad och försäljning Board/Management Information	2010-11-03	Swedish
Swedish Orphan Biovitrum appoints Anders Edvell as new Head of Sales and Marketing Board/Management Information	2010-11-03	English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ) Share Issue/Capital Change	2010-10-29	Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ) Share Issue/Capital Change	2010-10-29	English
Interim / Quarterly Report 2010 Interim / Quarterly Report 9M 2010	2010-10-26	Swedish
Interim / Quarterly Report 2010 Interim / Quarterly Report 9M 2010	2010-10-26	English
Symphogen och Swedish Orphan Biovitrum har erhållit särläkemedelsstatus i USA för Rozrolimupab för behandling av ITP Regulatory Filings	2010-10-06	Swedish
Symphogen and Swedish Orphan Biovitrum receive U.S. orphan drug designation for Rozrolimupab in ITP Regulatory Filings	2010-10-06	English
Swedish Orphan Biovitrum erhåller särläkemedelsklassificering (Orphan Drug Designation) inom EU för sitt långtidsverkande FVIIIFc produkt inom Hemofili A. Regulatory Filings	2010-09-23	Swedish
Swedish Orphan Biovitrum's Hemophilia A Therapy Receives European Commission Orphan Drug Designation Regulatory Filings	2010-09-23	English
Swedish Orphan Biovitrums distributionsavtal med Shire kommer att upphöra när Shire startar egen säljorganisation i Norden Regulatory Filings	2010-09-16	Swedish
Swedish Orphan Biovitrum's distribution agreements with Shire to be discontinued as Shire sets up own Nordic sales organization Regulatory Filings	2010-09-16	English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ) Share Issue/Capital Change	2010-08-31	Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ) Share Issue/Capital Change	2010-08-31	English
Swedish Orphan Biovitrums Kineret® har erhållit särläkemedelsstatus i USA Regulatory Filings	2010-08-26	Swedish
Swedish Orphan Biovitrum's Kineret® has Received Orphan Drug Designation in the USA Regulatory Filings	2010-08-26	English
Interim / Quarterly Report 2010 Interim / Quarterly Report Q2 2010	2010-07-20	Swedish
Interim / Quarterly Report 2010 Interim / Quarterly Report H1 2010	2010-07-20	English
Biogen Idec och Swedish Orphan Biovitrum presenterar data för långverkande hemofili B-behandling vid World Federation of Hemophilia Congress Regulatory Filings	2010-07-12	Swedish
Biogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Hemophilia B Therapy at the World Federation of Hemophilia Congress Regulatory Filings	2010-07-12	English
Biogen Idec och Swedish Orphan Biovitrum beslutar ta långverkande hemofili A-behandling in i registreringsstudie. Regulatory Filings	2010-07-09	Swedish
Biogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial Regulatory Filings	2010-07-09	English
Swedish Orphan Biovitrum och Dongbao bildar affärsallians för de kinesiska och europeiska marknaderna Regulatory Filings	2010-07-06	Swedish
Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets Regulatory Filings	2010-07-06	English
Byte av bolagsnamn för Biovitrum AB (publ) Delisting Announcement	2010-06-21	Swedish
Change of company name for Biovitrum AB (publ) Regulatory Filings	2010-06-21	English
Swedish Orphan Biovitrum och Biomodels avser att utveckla en metod för identifiering av risk för mukosit vid cancerbehandling Regulatory Filings	2010-05-11	Swedish
Swedish Orphan Biovitrum and Biomodels to develop assay for mucositis risk in cancer treatment Regulatory Filings	2010-05-11	English
Swedish Orphan Biovitrum presenterar positiva data från den första kliniska prövningen med Kiobrina® Regulatory Filings	2010-05-06	Swedish
Swedish Orphan Biovitrum presents first positive Kiobrina® clinical phase II data Regulatory Filings	2010-05-06	English
Ändring av antalet aktier och röster i Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2010-04-30	Swedish
New number of shares and votes in Biovitrum AB (publ) Share Issue/Capital Change	2010-04-30	English
Kommuniké från Biovitrums årsstämma AGM Information	2010-04-27	Swedish
Resolutions from Biovitrum's AGM AGM Information	2010-04-27	English
Interim / Quarterly Report 2010 Interim / Quarterly Report Q1 2010	2010-04-27	Swedish
Interim / Quarterly Report 2010 Interim / Quarterly Report Q1 2010	2010-04-27	English
Swedish Orphan Biovitrum har beslutat att gå vidare med Kiobrina® in i fas III Regulatory Filings	2010-04-21	Swedish
Swedish Orphan Biovitrum has decided to move Kiobrina® into phase III development Earnings Release FY 2010	2010-04-21	English
Swedish Orphan Biovitrum och Pharming tecknar avtal om distribution av Rhucin® Regulatory Filings	2010-04-15	Swedish
Swedish Orphan Biovitrum and Pharming sign Rhucin® distribution agreement Regulatory Filings	2010-04-15	English
Annual Report 2009 Annual Report FY 2009	2010-04-13	Swedish
Annual Report 2009 Annual Report FY 2009	2010-04-13	English
Swedish Orphan Biovitrum lanserar Willfact® inom ramen för sitt distributionsavtal med LFB BIOMEDICAMENTS Regulatory Filings	2010-04-08	Swedish
Swedish Orphan Biovitrum launches Willfact® under its distribution agreement with LFB BIOMEDICAMENTS Regulatory Filings	2010-04-08	English
Swedish Orphan Biovitrum erlägger betalning till tidigare säljare av Cambridge Biotechnology Limited Share Issue/Capital Change	2010-04-06	Swedish
Swedish Orphan Biovitrum makes payment to vendors of Cambridge Biotechnology Limited Share Issue/Capital Change	2010-04-06	English
Swedish Orphan Biovitrum utvidgar samarbetet med Merck Serono runt Cyanokit® Regulatory Filings	2010-04-01	Swedish
Swedish Orphan Biovitrum extends Cyanokit® cooperation with Merck Serono Regulatory Filings	2010-04-01	English
Swedish Orphan Biovitrum har träffat avtal med Amgen om ytterligare tillverkningsomgång av Kineret®-substans Regulatory Filings	2010-03-12	Swedish
Swedish Orphan Biovitrum has agreed to an additional Kineret® drug campaign with Amgen Regulatory Filings	2010-03-12	English
Earnings Release 2009 Earnings Release FY 2009	2010-02-18	Swedish
Interim / Quarterly Report 2009 Interim / Quarterly Report FY 2009	2010-02-18	English
Biogen Idec och Swedish Orphan Biovitrum uppdaterar Regulatory Filings	2010-02-18	Swedish
Biogen Idec and Swedish Orphan Biovitrum Update Capital/Financing Update	2010-02-18	English
Ändring av antalet aktier och röster i Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2010-01-29	Swedish
New number of shares and votes in Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2010-01-29	English
Major Shareholding Notification 2010 Major Shareholding Notification	2010-01-25	English
Biogen Idec och Swedish Orphan Biovitrum har inkluderat första patienten i global registreringsstudie av långverkande faktor IX för hemofili B-behandling Regulatory Filings	2010-01-25	Swedish
Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Acting Hemophilia B Therapy Regulatory Filings	2010-01-25	English
Major Shareholding Notification 2010 Major Shareholding Notification	2010-01-18	English
Major Shareholding Notification 2010 Major Shareholding Notification	2010-01-15	English
Declaration of Voting Results & Voting Rights Announcements 2010 Declaration of Voting Results & Voting Rights Announcements	2010-01-14	English
Biovitrum AB (publ) fullbordar förvärvet av Swedish Orphan International Holding AB och beslutar om apportemission Share Issue/Capital Change	2010-01-14	Swedish
Biovitrum AB (publ) completes the acquisition of Swedish Orphan International Holding AB and resolves on an issue in kind Share Issue/Capital Change	2010-01-14	English
Biovitrum AB:s (publ) företrädesemission fulltecknad Capital/Financing Update	2010-01-08	Swedish
Biovitrum AB’s (publ) rights issue fully subscribed Capital/Financing Update	2010-01-08	English

Filings by year

2026 16 filings
2025 35 filings
2024 29 filings
2023 48 filings
2022 23 filings
2021 31 filings
2020 44 filings
2019 38 filings
2018 31 filings
2017 34 filings
2016 47 filings
2015 52 filings
2014 58 filings
2013 79 filings
2012 65 filings
2011 51 filings
2010 78 filings
2009 69 filings
2008 51 filings
2007 10 filings